Biotech

All Articles

AstraZeneca blog posts information on in-house rivals to AbbVie, Pfizer ADCs

.AstraZeneca has actually shared an early look at the functionality of its own in-house antibody-dru...

iTeos- GSK's TIGIT superstar reveals purposeful enhancement

.After introducing a period 3 launch based upon favorable midstage outcomes, iTeos and GSK are actua...

More joint FDA may accelerate unusual illness R&ampD: report

.The FDA ought to be actually more open as well as collaborative to unleash a surge in commendations...

Zenas, MBX, Bicara scalp to Nasdaq in warm time for biotech IPOs

.It's an uncommonly hectic Friday for biotech IPOs, along with Zenas BioPharma, MBX and also Bicara ...

Atea's COVID antiviral fails to halt hospitalizations in phase 3

.Atea Pharmaceuticals' antiviral has actually fallen short one more COVID-19 trial, yet the biotech ...

Neurocrine's offer to conserve schizophrenia prospect stops working

.Neurocrine Biosciences' mental illness plan pivot has actually stopped working. The biotech was act...

Sanofi pays out $110M upfront for late-stage radioligand treatment

.Sanofi has actually brought in a late entry to the radioligand gathering, paying for 100 thousand e...

F 2G brings up $100M for 2nd try to obtain brand-new antifungal to market

.After F2G's 1st effort to acquire a new training class of antifungal to market was actually deraile...

Moderna targets $1.1 B in R&ampD costs slices, drops 5 courses in the middle of earnings pressures

.Moderna has promised to cut R&ampD investing through $1.1 billion through 2027. The choice to retra...

Sanofi's $80M bank on Fulcrum dystrophy medicine ends in phase 3 go bust

.Only four months after Sanofi wager $80 million in ahead of time money on Pivot Therapies' losmapim...